We are developing a novel, effective and proprietary cancer treatment

Anastasis’ Technology

The technology relates to a novel treatment applicable to many cancers.

These cancers depend on rogue cells multiplying uncontrollably caused by DNA abnormalities (mutations) in important pathways involved in the generation of cancer and cancer stem cells. When there are mutations in these pathways, cancer cells and cancer stem cells, run rogue, multiply and spread uncontrollably.

Anastasis has the technology to control this process, as follows:

Take a biopsy (current procedure).

Analyse tumour tissue for critical mutations. This is a simple test using established technology.

Select patients whose tumours have critical mutations.

Treat selected patients with the matching pathway inhibitor. Anastasis has several pathways inhibitors ready for development.

The Development

The Anastasis Biotec Ltd drugs need to go through pre-clinical testing and subsequently clinical trials. Clinical efficacy data are expected in four to five years from now.

The Investment

Anastasis Biotec Ltd is raising funds in return for equity to conduct preclinical and clinical ‘proof of concept’ trials.

The Team

Anastasis Biotec has put together an exceptional team to carry the company forward to a successful outcome.

Summing up

Anastasis Biotec is developing a novel and proprietary treatment; tailor made for patients with cancers that express specific ‘cancer driving mutations’.

This treatment, by targeting specific and critical mutations, could potentially provide a breakthrough in the treatment of cancer types with significant clinical unmet need.

Got a Question?

Background and News

Discovery Science - Stem Cell Universe with Stephen Hawking

Anastasis Cancer Stem Cells Treatment Efforts

Anastasis Completed Funding

Anastasis has raised funding through Crowdcube, in excess of £150,000, which was its initial objective, allowing the Company to accelerate its R+D program and also support research into stability and cellular activity of its drug compounds at the University of Chicago, USA.

COVID‑19 in the heart and the lungs: could we “Notch” the inflammatory storm?

Editorial : Basic Research in Cardiology 2020, 115:31
Paola Rizzo University of Ferrara, Italy

ASCO Annual Meeting 2020, May 29 - June 1

Abstract 17601, A clinical trial without patients, UK and Cyprus

This is an innovative molecular imaging ‘phase I/II’ trial assessing biodistribution, PK, PD, mode of action , toxicity and efficacy of a novel Mastermind inhibitor prior to entering the clinic.